Kobe University · University Hospital · 講師

Research keywords非小細胞肺癌・肺腺癌・ロボット支援胸腔鏡手術・肺区域切除術・術前化学免疫療法・サルベージ手術・肺神経内分泌癌・自然気胸手術・Psf3・肺血管CT解析

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Preoperative Immune-Related Adverse Events in Resectable NSCLC Treated With Neoadjuvant Nivolumab Plus Chemotherapy: A Multicenter Retrospective Analysis2026 · Elsevier BV, 2026年01月, JTO Clinical and Research Reports, 7(1) (1), 100930 - 100930
• The Future Direction of Artificial-Intelligence-Aided Thoracic Surgery.2025 · 2025年09月, Annals of surgical oncology, 32(9) (9), 6203 - 6204, 英語, 国際誌
• The Crucial Value of Glutathione Peroxidase 2 to Understand the 'Two-Faced' Role of Reactive Oxygen Species in Lung Adenocarcinoma.2024 · 2024年08月, Annals of surgical oncology, 31(8) (8), 4849 - 4850, 英語, 国際誌
• Safety Profile of Neoadjuvant Chemoimmunotherapy with Nivolumab for Patients with Resectable NSCLC in the Real-world (CReGYT-04 Neo-Venus).2023 · BACKGROUND: This real-world study aimed to investigate feasibility and profile of adverse events (AEs) associated with neoadjuvant chemoimmunotherapy in patients with resectable non-small cell lung cancer (NSCLC) in the real-world. METHODS: We conducted a multicenter retrospective study using real-world data of patients with resectable stage II-III NSCLC treated with neoadjuvant chemoimmunotherapy with nivolumab between March 2023 and July 2024 at 29 Japanese institutions. The safety, AE profiles, and risk factors for grade 3 or higher AEs were evaluated. RESULTS: A total of 126 patients were analyzed. In the neoadjuvant phase, grade 3 or higher treatment-related AEs and immune-related AEs (irAEs) occurred in 36 (28.6%) and 12 (9.5%) patients, respectively. One patient (0.8%) died from a neoadjuvant treatment-related AE of cytokine storm and subsequent multi-organ failure. Definitive surgery after neoadjuvant treatment was performed in 114 patients (90.5%), with only one death within 90 days of surgery. Half of endocrine-related irAEs occurred in the postoperative phase. Among the demographic characteristics, a history of coronary artery disease (CAD) was a significant risk factor for grade 3 or higher treatment-related AEs (odds ratio [OR] = 16.556, [95% confidence interval [CI] = 1.698-161.479], P = 0.016) and irAEs (OR = 10.196, [95% CI = 1.193-87.166], P = 0.034). CONCLUSIONS: Real-world data from the era of neoadjuvant chemoimmunotherapy showed feasibility consistent with the results of randomized controlled trials. The incidence of grade 3 or higher AEs was not particularly high but was clinically significant, and a history of CAD may be a predictor.

• Ex vivo lung perfusionを用いた新しい臓器保存法の確立 田中 雄悟, 重村 周文, 田根 慎也 日本学術振興会, 科学研究費助成事業, 若手研究(B), 神戸大学, 2014年04月01日 - 2016年03月31日 肺移植における臓器保存は冷保存が一般的であるが、近年Ex vivo lung perfusion（EVLP）が臨床応用されている。我々は、これまでEVLPで重要視されていなかった気管支動脈にも還流液を流すシステム（Dual EVLPシステム）を考案し、その効果を検証した。その結果、①Airway Hypoxia の克服、②肺組織のmetabolism の改善により我々の方法が従来よりも良好な臓器保存法になる可能性が示唆された。2014 · KUID parsed section
• Ex vivo lung perfusionを用いた新しい臓器保存法の確立

• Official profile